AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3622314 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of isosorbide 20 mg 3 times daily
Number of subjects: 136
Study 1982280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg epinastine
Number of subjects: 15
Study 1982280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg epinastine
Number of subjects: 15
Study 1982280 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg epinastine
Number of subjects: 15
Study 1982280 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 15
Study 1982280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4207965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(2)
Number of subjects: 23
Study 4207965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30251299 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) breathing with a 5-cm H2O expiratory load
Number of subjects: 13
Study 30251299 — intervention group
Group type: COMPARATOR
Intervention: Sham (no load)
Number of subjects: 13
Study 30251299 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) breathing
Number of subjects: 13
Study 28321027 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 21
Study 28321027 — intervention group
Group type: EXPERIMENTAL
Intervention: Azosemide
Number of subjects: 21
Study 26561784 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g bioactive collagen peptides (BCP) daily for 6 months
Number of subjects: 105
Study 26561784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 25177910 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel weight-loss intervention
Number of subjects: 13
Study 25177910 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 20884344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic-absolute exercise (50%W(max) under 15%O₂, H-AT) for 30 min/day, 5 days/week for 4 weeks
Number of subjects: 50
Study 20884344 — intervention group
Group type: COMPARATOR
Intervention: Normoxic resting (N-C)
Number of subjects: 50
Study 20884344 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic resting (H-C)
Number of subjects: 50
Study 20884344 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise (N-T)
Number of subjects: 50
Study 20884344 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic-relative exercise (H-RT)
Number of subjects: 50
Study 19808198 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE‐A3 antigen‐specific cancer immunotherapeutic (ASCI) agents
Number of subjects: 0
Study 17582289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile group of MPO level
Number of subjects: 176
Study 17582289 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO level > or = 62.9 AUU/L
Number of subjects: 176
Study 17582289 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO level when TnI <= 0.05 ng/ml
Number of subjects: 176
Study 15364316 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1518
Study 15364316 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo with open-label antihypertensive therapy)
Number of subjects: 1518
Study 12389143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 62
Study 12389143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 2000 mg/day
Number of subjects: 62
Study 12389143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 62
Study 9661119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg recombinant human growth hormone (rhGH)
Number of subjects: 8
Study 9661119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg recombinant human growth hormone (rhGH)
Number of subjects: 8
Study 9661119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg rhGH
Number of subjects: 8
Study 9661119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rhGH
Number of subjects: 8
Study 8748042 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐fenfluramine
Number of subjects: 30
Study 8748042 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 30
Study 8748042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2497136 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% CO2
Number of subjects: 0
Study 2497136 — intervention group
Group type: COMPARATOR
Intervention: 5% CO2 in air
Number of subjects: 0
Study 408287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone (Tanderil)
Number of subjects: 24
Study 408287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30312586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vazirani‐Akinosi (VA) nerve block
Number of subjects: 200
Study 30312586 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve (IAN) block
Number of subjects: 200
Study 28279967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d
Number of subjects: 24
Study 28279967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25906824 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers for Medicare & Medicaid Services hospital-acquired conditions policy
Number of subjects: 569
Study 25906824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpolicy period
Number of subjects: 569
Study 23425012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 to 5 mg
Number of subjects: 546
Study 23425012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 546
Study 23425012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 21188654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs‐Tx)
Number of subjects: 56
Study 21188654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cell therapy)
Number of subjects: 56
Study 19690393 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Apex (RVA) pacing
Number of subjects: 122
Study 19690393 — intervention group
Group type: COMPARATOR
Intervention: Right Ventricular Outflow Tract (RVOT) pacing
Number of subjects: 122
Study 17377401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) - 2 puffs administered at 0, 20, 40 min
Number of subjects: 21
Study 17377401 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (T) - 2 puffs administered at 0, 20, 40 min
Number of subjects: 21
Study 15188805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 20 mg/kg i.v. within first six hours of life
Number of subjects: 0
Study 15188805 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11683930 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus AMPC 750 mg and CAM 200 mg b.i.d. (Group B-LAC200)
Number of subjects: 0
Study 11683930 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg, AMPC 750 mg and CAM 400 mg b.i.d. (Group C-LAC400)
Number of subjects: 0
Study 11683930 — intervention group
Group type: COMPARATOR
Intervention: LPZ 30 mg twice a day (Group A-LPZ-only)
Number of subjects: 0
Study 10530103 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (RMGI) restorative materials
Number of subjects: 0
Study 10530103 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite resin
Number of subjects: 0
Study 7915733 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 534
Study 7915733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study 2917701 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 16
Study 2917701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily) + Lovastatin (20 mg twice daily)
Number of subjects: 16
Study 2917701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2917701 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin alone
Number of subjects: 16
Study 4897625 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 4897625 — intervention group
Group type: COMPARATOR
Intervention: Control (water test meal)
Number of subjects: 0
Study 30142037 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional tray-delivered system (10% hydrogen peroxide)
Number of subjects: 60
Study 30142037 — intervention group
Group type: EXPERIMENTAL
Intervention: Strips (White Strips, Oral-B)
Number of subjects: 60
Study 30142037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled disposable trays (Opalescence Go, Ultradent)
Number of subjects: 60
Study 30142037 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (10% hydrogen peroxide)
Number of subjects: 60
Study 30020943 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing an apple
Number of subjects: 20
Study 30020943 — intervention group
Group type: COMPARATOR
Intervention: Brushing teeth
Number of subjects: 20
Study 29906024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 68
Study 29906024 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 68
Study 24271159 — intervention group
Group type: EXPERIMENTAL
Intervention: Extralevator abdominoperineal excision (ELAPE)
Number of subjects: 20
Study 24271159 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominoperineal excision (SAPE)
Number of subjects: 20
Study 22424039 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration and salvage of superficial branches of the saphenous nerve
Number of subjects: 98
Study 22424039 — intervention group
Group type: COMPARATOR
Intervention: No exploration of the saphenous nerve
Number of subjects: 98
Study 22424039 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of 98 patients
Number of subjects: 98
Study 22424039 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 98
Study 19486269 — intervention group
Group type: EXPERIMENTAL
Intervention: oral and denture hygiene instructions
Number of subjects: 11
Study 19486269 — intervention group
Group type: EXPERIMENTAL
Intervention: instructions associated with the home use of a disclosing agent (1% neutral red)
Number of subjects: 11
Study 17498020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg x kg(‐1)
Number of subjects: 93
Study 17498020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 microg x kg(‐1)
Number of subjects: 93
Study 17498020 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 93
Study 15682849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m ethylenedicysteine (3.7 MBq/kg body weight) and furosemide at an appropriate dose administered intravenously
Number of subjects: 133
Study 15682849 — intervention group
Group type: EXPERIMENTAL
Intervention: F+0 diuresis renography
Number of subjects: 133
Study 11568738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UVA1 phototherapy (<=130 J/cm2)
Number of subjects: 10
Study 11568738 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose UVA1 phototherapy (half the dose of high-dose)
Number of subjects: 10
Study 9586911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, and prednisone (COP)
Number of subjects: 234
Study 9586911 — intervention group
Group type: COMPARATOR
Intervention: Prednimustine and mitoxantrone (PmM)
Number of subjects: 234
Study 9586911 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) maintenance
Number of subjects: 234
Study 9586911 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 234
Study 7978187 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate-fentanyl
Number of subjects: 19
Study 7978187 — intervention group
Group type: COMPARATOR
Intervention: midazolam-fentanyl
Number of subjects: 19
Study 2594037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (3000 cGy of electron-beam radiation + parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine)
Number of subjects: 103
Study 2594037 — intervention group
Group type: COMPARATOR
Intervention: Sequential topical treatment
Number of subjects: 103
Study 2594037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 103
Study 2594037 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy and Sequential topical treatment
Number of subjects: 103
Study 4804456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet alone
Number of subjects: 23
Study 4804456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet with fenfluramine
Number of subjects: 23
Study 4804456 — intervention group
Group type: COMPARATOR
Intervention: Diabetics not on any form of treatment
Number of subjects: 23
Study 31979019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-enriched food products
Number of subjects: 29
Study 31979019 — intervention group
Group type: COMPARATOR
Intervention: Fiber-enriched drinks
Number of subjects: 29
Study 31409915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg in addition to baseline dose of statin
Number of subjects: 21
Study 31409915 — intervention group
Group type: COMPARATOR
Intervention: Double-dose statin therapy
Number of subjects: 21
Study 29020936 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered sugammadex (1 mg/kg before extubation and 1 mg/kg after extubation)
Number of subjects: 120
Study 29020936 — intervention group
Group type: COMPARATOR
Intervention: Single bolus sugammadex (2 mg/kg)
Number of subjects: 120
Study 29020936 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.02 mg/kg with glycopyrrolate)
Number of subjects: 120
Study 25835160 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol
Number of subjects: 32
Study 25835160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23455877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone with counseling for 4 months followed by standard methadone with counseling
Number of subjects: 230
Study 23455877 — intervention group
Group type: COMPARATOR
Intervention: Methadone without counseling for 4 months followed by standard methadone with counseling
Number of subjects: 230
Study 23455877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment (both with and without counseling)
Number of subjects: 230
Study 21909060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorial saturation
Number of subjects: 28
Study 21909060 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution
Number of subjects: 28
Study 18237355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 448
Study 18237355 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin monotherapy
Number of subjects: 448
Study 18237355 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatments (MVP, vinorelbine, active symptom control)
Number of subjects: 448
Study 17214378 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing from the central position with the near row having more lights
Number of subjects: 0
Study 17214378 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing from a lateral position
Number of subjects: 0
Study 17214378 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional stimuli
Number of subjects: 0
Study 12828724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyto-SED™ system (CS)
Number of subjects: 137
Study 12828724 — intervention group
Group type: COMPARATOR
Intervention: Direct smear (DS) technique
Number of subjects: 137
Study 10987238 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus manual lymphatic drainage (MLD) 8 times in 2 weeks and training in self-massage
Number of subjects: 42
Study 10987238 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (compression garment, exercises, information about lymphedema and skin care)
Number of subjects: 42
Study 8993089 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 25
Study 8993089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8291869 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate (PEP) 160 mg/month
Number of subjects: 147
Study 8291869 — intervention group
Group type: COMPARATOR
Intervention: LHRH analog (buserelin)
Number of subjects: 147
Study 8291869 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 147
Study 3034016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (HOE 498) 5 or 10 mg
Number of subjects: 34
Study 31197506 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium lactis
Number of subjects: 97
Study 31197506 — intervention group
Group type: COMPARATOR
Intervention: Non-probiotic formula
Number of subjects: 97
Study 29790415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390
Study 24507830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluticasone (1,000 μg/d)
Number of subjects: 64
Study 24507830 — intervention group
Group type: COMPARATOR
Intervention: Low-dose fluticasone (250 μg/d)
Number of subjects: 64
Study 24507830 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of PC20
Number of subjects: 64
Study 23129488 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg to 12 mg depending on response)
Number of subjects: 146
Study 23129488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 20233199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg)
Number of subjects: 20
Study 18621928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 543
Study 18621928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg once daily
Number of subjects: 543
Study 18621928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg once daily
Number of subjects: 543
Study 18621928 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (low-molecular-weight heparin followed by vitamin K antagonists)
Number of subjects: 543
Study 16100132 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management (DM) program with care coordination, family support, teaching, and monitoring of therapies from a team of advanced-practice nurses, a geriatrician, and a pulmonologist for 2 months post-hospital discharge.
Number of subjects: 334
Study 16100132 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 334
Study 16100132 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management (DM) program.
Number of subjects: 334
Study 12358171 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 236
Study 12358171 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 236
Study 10354963 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine combination tablet after an overnight fast
Number of subjects: 24
Study 10354963 — intervention group
Group type: COMPARATOR
Intervention: lamivudine 150 mg tablet and zidovudine 300 mg tablet administered concurrently after an overnight fast
Number of subjects: 24
Study 10354963 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine combination tablet 5 minutes after a standardized high-fat breakfast
Number of subjects: 24
Study 7796357 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 40
Study 7796357 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg four times daily
Number of subjects: 40
Study 2309640 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (less than 500 kcal/d) with different compositions
Number of subjects: 5
Study 2309640 — intervention group
Group type: COMPARATOR
Intervention: Conventional 1200-kcal/d hypocaloric diet
Number of subjects: 5
Study 2309640 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (less than 500 kcal/d)
Number of subjects: 5
Study 678769 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of depot penicillin at the time of suture
Number of subjects: 285
Study 678769 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic cover
Number of subjects: 285
Study 31003515 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial nutritional intervention
Number of subjects: 0
Study 31003515 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial physical activity intervention
Number of subjects: 0
Study 31003515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27480573 — intervention group
Group type: EXPERIMENTAL
Intervention: Equicrestal implants (G1, n=28)
Number of subjects: 55
Study 27480573 — intervention group
Group type: COMPARATOR
Intervention: Subcrestal implants (G2, n=27)
Number of subjects: 55
Study 26156901 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean 500 mg/day)
Number of subjects: 90
Study 26156901 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (mean 5.2 mg/day)
Number of subjects: 90
Study 23339638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) with a Novalung R100 ventilator (Metran)
Number of subjects: 795
Study 23339638 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (usual ventilatory care)
Number of subjects: 795
Study 20931220 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 19
Study 19469706 — intervention group
Group type: EXPERIMENTAL
Intervention: sorivudine cream
Number of subjects: 25
Study 19469706 — intervention group
Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 25
Study 16753975 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO) administered twice-daily for 15 min duration plus standard care
Number of subjects: 9
Study 16753975 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 9
Study 16753975 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO)
Number of subjects: 9